Pluristem Updates Cell Manufacturing Industry on Its Proprietary 3D Cell Expansion Technology at Industry Conference
HAIFA, Israel, Jan 22, 2013 (GLOBE NEWSWIRE via COMTEX) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that Senior Scientists at Pluristem will be presenting updated developments relating to the company's proprietary 3D cell expansion technology. These innovations will be implemented in Pluristem's new state-of-the-art manufacturing facility for expansion of placental-derived mesenchymal-like Adherent Stromal Cells (ASCs).
The presentations will take place at Engineering Conferences International's Scale-Up and Manufacturing of Cell-Based Therapies II Conference to be held January 21-23, 2013 at the Hyatt Regency Mission Bay Spa and Marina in San Diego, California.
Ohad Karnieli PhD, MBA and VP of Development at Pluristem will give an oral presentation entitled, "Bioreactors in Cell Therapy, the Advantages of High-Throughput Culturing Technologies and the Downstream Challenges". During this talk, Dr. Karnieli will present Pluristem's new production line and demonstrate how the company has drawn on its vast experience in high-throughput culturing to solve many of the problems related to the mass production of ASCs. Dr. Karnieli's presentation will be made available at the company's website pluristem.com for the next 30 days.
Eytan Abraham PhD and Product Innovation Research Manager at Pluristem will give a poster presentation entitled, "From Gene Expression to In Vivo Models - Characterization and Potential Therapeutic Properties of Placenta Derived Mesenchymal-Like Adherent Stromal Cells". In this poster, Dr. Abraham will be addressing the specific changes that occur in gene regulation and protein secretion when ASCs are grown in a 3D culturing phase and the biological changes and therapeutic advantages of implementing this technology in the mass expansion of ASCs use |
